logo-loader

PreveCeutical seeing significant hospital interest for breakthrough Cannabidiol treatment

Published: 01:20 28 Feb 2018 AEDT

Stephen Van Deventer, chairman and CEO of PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) and chief research officer Dr Harry Parekh discuss with Proactive the health sciences specialist's four exciting programmes.

Their most advanced is centred around Cannabidiol (CBD) - a non-psychoactive compound found in the cannabis plant and is now widely used to treat chronic pain, multiple sclerosis and other conditions.

Some evidence even suggests it can prevent symptoms of Alzheimer’s and appears to promote the death of cancer cells.

PreveCeutical prepares for the final stage of their Sol-Gel program

PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked...

on 27/4/19